Skip to content
Peptide research

DA-1726

Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

DA-1726 is an experimental dual GLP-1/glucagon agonist studied for weight loss and liver fat reduction. The case rests on one small Phase 1 trial: weight and waist losses look promising, but glucose and liver-stiffness signals are weak, with no larger trials yet. GI effects are common, and its glucagon activity carries a theoretical risk of raising blood sugar. Not an approved drug, with no long-term safety data and only unregulated research-grade supply.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

DA-1726 is a novel dual oxyntomodulin (OXM) analogue that functions as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, developed by MetaVia Inc. (formerly NeuroBo Pharmaceuticals; DA-1726 licensed from Dong-A ST) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Unlike GLP-1/GIP dual agonists like tirzepatide, DA-1726 combines GLP-1 activity with glucagon receptor activation, which is believed to increase energy expenditure, promote visceral fat loss, and provide direct liver benefits through enhanced fatty acid oxidation.

In Phase 1 clinical trials, DA-1726 produced early weight loss without dose titration. In the highest non-titrated cohort, given weekly for 8 weeks, participants achieved an average weight loss of 9.1% and a 9.8 cm reduction in waist circumference by Day 54. That cohort also showed a 12.3 mg/dL improvement in fasting glucose and a 23.7% reduction in liver stiffness, suggesting possible hepatic effects beyond weight loss alone. No treatment-related discontinuations occurred in that cohort, and GI side effects were mild to moderate.

MetaVia began Phase 1 Part 3 in April 2026. Completion of titration was announced in July; 16-week topline results are expected in Q4 2026. The company positions DA-1726 as having 'best-in-class' potential among GLP-1/glucagon dual agonists, citing its tolerability without titration, glucose-lowering without hyperglycemia risk, and early liver benefit signals.

How it works in the body

A dual agonist of GLP-1 and glucagon receptors based on an oxyntomodulin analog. GLP-1 activation reduces appetite and improves insulin sensitivity, while glucagon receptor activation increases hepatic energy expenditure and fat oxidation, targeting liver fat specifically.

Research overview

DA-1726 is being developed by MetaVia Inc. (Nasdaq: MTVA), formerly NeuroBo Pharmaceuticals's US subsidiary. The Phase 1 program is a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses in obese but otherwise healthy adults (BMI 30-45 kg/m2). Phase 1 Part 1 and Part 2 evaluated doses from 4 mg to 48 mg weekly, with 9 participants per cohort randomized 6:3 active:placebo. At 32 mg (4 weeks), participants achieved 4.3% mean weight loss and up to 6.3% maximum, with waist circumference reduction of up to 3.9 inches. PK data confirmed linear, dose-proportional exposure and a mean half-life of approximately 80 hours, supporting once-weekly dosing. The 48 mg cohort (8 weeks, non-titrated) showed 9.1% mean weight loss by Day 54 with 9.8 cm waist circumference reduction, 12.3 mg/dL fasting glucose improvement, and 23.7% liver stiffness reduction. In the 48 mg cohort, no serious adverse events or treatment-related discontinuations were reported. No clinically meaningful cardiovascular changes were observed in that cohort. An earlier 8 mg cohort included an unrelated serious adverse event and study discontinuation following a car accident. Phase 1 Part 3 began in April 2026 with planned enrollment of approximately 40 subjects evaluating one-step (16 mg to 48 mg) and two-step (16 mg to 32 mg to 64 mg) titration over 16 weeks. In preclinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide with superior lipid-lowering effects, and similar weight loss to tirzepatide and survodutide while preserving lean body mass.

Who researches DA-1726?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Gastrointestinal adverse events (mild to moderate)

    Moderate

    MetaVia Phase 1 topline release, January 2026 and EASL Congress 2026 release; GLP-1 receptor agonist class labeling, e.g. FDA-approved semaglutide (Wegovy) prescribing information available via accessdata.fda.gov

  • Very limited clinical data (Phase 1 only)

    High

    MetaVia Phase 1 program disclosures; ClinicalTrials.gov NCT06252220.

  • Glucagon-mediated hyperglycemia risk (theoretical)

    Theoretical

    MetaVia Phase 1 topline release, January 2026; general class background on GLP-1/glucagon dual agonism.

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionModerate

    Adding a GLP-1 receptor agonist to insulin substantially raises hypoglycemia risk, and approved GLP-1 labels direct consideration of a reduction in concomitant insulin dose. DA-1726 has never been studied in insulin-treated patients, so this is class-based extrapolation, not molecule-specific data.

    FDA-approved semaglutide prescribing information (Wegovy/Ozempic), Warnings and Drug Interactions sections, via accessdata.fda.gov

  • Sulfonylureas (glipizide, glyburide, glimepiride) and meglitinides

    CautionModerate

    Insulin secretagogues combined with incretin agonists produce clinically significant hypoglycemia and generally require secretagogue dose reduction. No DA-1726-specific data exist, and there is no evidence that the molecule's glucagon arm reliably offsets this risk.

    FDA GLP-1 receptor agonist class labeling (semaglutide, liraglutide, tirzepatide), Drug Interactions sections

  • Other GLP-1 or incretin agonists (semaglutide, tirzepatide, liraglutide, retatrutide)

    CautionModerate

    Concurrent use is pharmacologically duplicative and would be expected to compound GI intolerance and anorexia with no studied benefit. No combination data exist for DA-1726. Note this is mechanism-based reasoning plus the general absence of concomitant-use data in labeling, rather than a specific labeled contraindication.

    Mechanism-based; concomitant use of two incretin-based agents is not studied in the approved-product labeling for any GLP-1 receptor agonist

  • Narrow-therapeutic-index oral drugs (levothyroxine, warfarin, oral contraceptives, immunosuppressants)

    CautionLow

    GLP-1 receptor agonism delays gastric emptying and can alter the rate — occasionally the extent — of oral drug absorption, so INR, TSH, and drug levels warrant monitoring after initiation or dose change. The best-documented specific case in labeling is oral contraceptive efficacy with tirzepatide; levothyroxine, warfarin, and immunosuppressants are extrapolation. DA-1726 has no published dedicated drug-drug interaction studies.

    FDA-approved semaglutide and tirzepatide prescribing information, Drug Interactions (delayed gastric emptying) sections, via accessdata.fda.gov

  • General anesthesia / procedural sedation (elective surgery, endoscopy)

    CautionModerate

    Delayed gastric emptying from GLP-1 receptor agonists has been associated with retained gastric contents and aspiration risk under anesthesia. The 2023 ASA consensus advised holding weekly agents for one week pre-procedure, but the subsequent multisociety guidance moved toward individualized risk assessment (symptom screening, gastric ultrasound, clear-liquid diet, full-stomach precautions) rather than routine withholding. If DA-1726's reported multi-day half-life is accurate, washout would be slow, making pre-procedural risk assessment the operative safeguard.

    American Society of Anesthesiologists 2023 consensus-based guidance on GLP-1 receptor agonists and the subsequent multisociety clinical practice guidance on periprocedural management (asahq.org)

  • Metformin

    SynergisticLow

    Complementary mechanisms with low intrinsic hypoglycemia risk. Metformin is standard background therapy in GLP-1 trials and no clinically meaningful pharmacokinetic interaction is expected, though additive GI upset is common. No DA-1726-specific combination data.

    Metformin and GLP-1 receptor agonist class labeling; combination is standard background therapy in GLP-1 RA trial designs

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Non-overlapping mechanisms with additive weight and glycemic benefit demonstrated for GLP-1 receptor agonists as a class; an additive effect on liver fat has not been established. Practical cautions are volume depletion and, in people with diabetes, euglycemic ketoacidosis if caloric intake falls sharply on a strongly anorectic agent. No DA-1726-specific data.

    Class-level randomized evidence for GLP-1 RA plus SGLT2 inhibitor combination therapy in type 2 diabetes.

  • Systemic corticosteroids

    CautionTheoretical

    Steroid-induced hepatic gluconeogenesis and insulin resistance could compound the glucagon-receptor arm of DA-1726 and blunt or reverse its glycemic benefit. This is mechanistic reasoning only; it has not been observed with this molecule and no corticosteroid-treated patients have been studied.

    Mechanism-based reasoning from corticosteroid and glucagon-receptor pharmacology; no DA-1726 or GLP-1/glucagon dual-agonist interaction data

Known risks(3)

  • Gastrointestinal adverse events (mild to moderate)

    Mild to Moderate

    GI events were reported across dose cohorts but were mild to moderate and transient. No treatment discontinuations occurred due to GI events in any cohort.

  • Very limited clinical data (Phase 1 only)

    Only approximately 80 participants have been exposed. Small sample sizes may not capture rare adverse events. Long-term safety, cardiovascular outcomes, and effects in diverse populations are unknown.

  • Glucagon-mediated hyperglycemia risk (theoretical)

    Theoretical

    Glucagon receptor activation can raise blood glucose. However, Phase 1 data showed glucose improvements rather than elevations, suggesting the GLP-1 component adequately counterbalances glucagon effects.

Drug interactions(3)

  • Insulin and insulin secretagogues

    GLP-1 receptor activation enhances insulin secretion; co-administration may increase hypoglycemia risk. However, the glucagon component may partially offset this.

  • Other GLP-1 or incretin-based therapies

    Co-administration not recommended due to overlapping mechanisms and risk of additive GI side effects.

  • Oral medications with narrow therapeutic index

    GLP-1 agonists slow gastric emptying, potentially altering absorption of co-administered oral drugs.

Research & benefits

Evidence base

Evidence Level
Early Evidence (Phase 1)
Total Studies
3
Human Studies
80

DA-1726 has completed Phase 1 single and multiple ascending dose cohorts. The 48 mg non-titrated cohort showed 9.1% weight loss at 8 weeks with no serious adverse events or treatment-related discontinuations. However, only small numbers of participants have been studied (approximately 9 per cohort), and no Phase 2 or Phase 3 data are available. Phase 1 Part 3 began in April 2026; dose-titration completion was announced in July, with 16-week results expected in Q4 2026.

Researched for(6)

Rated by confidence in the evidence

  • Robust early weight loss (9.1% at 8 weeks without dose titration)

    Medium

    Small randomized Phase 1 trial; the 8-week extension figure lacked a placebo comparison.

    MetaVia Phase 1 topline release, January 2026, and EASL Congress 2026 presentation (company investor-relations and PR Newswire releases). The registered program is a Phase 1 SAD/MAD study.

  • Significant waist circumference reduction (9.8 cm at Day 54) suggesting visceral fat targeting

    Medium

    Placebo-controlled human data on waist size; visceral fat targeting is inferred, not measured directly.

    MetaVia Phase 1 topline release, January 2026, and EASL Congress 2026 poster summary

  • Fasting glucose improvement (12.3 mg/dL from baseline of 105.3 mg/dL)

    Low

    Single small study, no placebo comparison reported, from a near-normal baseline glucose level.

    MetaVia Phase 1 topline release, January 2026

  • Liver stiffness reduction of 23.7% suggesting direct hepatic benefit

    Speculative

    Exploratory FibroScan findings included a placebo comparison. A clinically meaningful liver benefit remains unproven.

    MetaVia EASL Congress 2026 release and Phase 1 topline release, January 2026 (company-reported figures)

  • Favorable tolerability with no treatment discontinuations (no titration needed)

    Low

    Reported in about six subjects only, too few a sample to establish tolerability.

    MetaVia EASL Congress 2026 release and Phase 1 topline release, January 2026

  • Once-weekly dosing supported by 80-hour half-life

    Medium

    Phase 1 data reported a mean half-life near 80 hours at the 32 mg dose, supporting once-weekly dosing.

    MetaVia press release, "MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek 2025," PR Newswire, Nov 4 2025 (https://www.prnewswire.com/news-releases/metavia-to-present-new-phase-1-and-pre-clinical-data-on-da-1726-at-obesityweek-2025-302604527.html).

Benefits(6)

  • Robust early weight loss (9.1% at 8 weeks without dose titration)

    Phase 1 48 mg MAD cohort (MetaVia press release Jan 2026)

  • Significant waist circumference reduction (9.8 cm at Day 54) suggesting visceral fat targeting

    Phase 1 48 mg cohort (DDW Online Jan 2026)

  • Fasting glucose improvement (12.3 mg/dL from baseline of 105.3 mg/dL)

    Phase 1 48 mg cohort (MetaVia press release)

  • Liver stiffness reduction of 23.7% suggesting direct hepatic benefit

    Phase 1 48 mg cohort — VCTE measurement (MetaVia data)

  • Favorable tolerability with no treatment discontinuations (no titration needed)

    Phase 1 all cohorts — no SAEs, no discontinuations, mild/moderate GI events

  • Once-weekly dosing supported by 80-hour half-life

    Phase 1 PK data (ObesityWeek 2025 poster)

Key studies(2)

  1. Phase 1 Multiple Ascending Dose Study of DA-1726 — 48 mg Cohort Results

    Phase 1 MADn=9 (48 mg cohort); ~36 total across 4 dose cohorts8 weeks (48 mg); 4 weeks (lower doses)

    MetaVia Inc. investigators

    MetaVia press release / DDW Online

    2026

    Non-titrated 48 mg weekly dosing achieved 9.1% mean weight loss by Day 54, 9.8 cm waist circumference reduction, 12.3 mg/dL fasting glucose improvement, and 23.7% liver stiffness reduction. No treatment discontinuations. All GI AEs mild to moderate.

  2. Phase 1 Part 3 — Dose Titration Study of DA-1726 (16-week, up to 64 mg)

    Phase 1 (ongoing)n=40 planned (20 per part)16 weeks

    MetaVia Inc.

    MetaVia press release (March 2026)

    2026

    IRB approved. Part 3A: one-step titration (16 mg for 4 weeks, then 48 mg for 12 weeks). Part 3B: two-step titration (16 mg, 32 mg, then 64 mg). Dosing began in April 2026; 16-week results are expected in Q4 2026.

Regulation & availability

Why researchers look at it

DA-1726 represents the next frontier in GLP-1-based obesity treatment — combining GLP-1 with glucagon receptor activation to potentially burn more calories, target visceral fat directly, and improve liver health. Its remarkable early results (9.1% weight loss in 8 weeks with no titration) make it one of the most exciting early-stage metabolic drugs to watch.

Estimated cost
Not yet available — Phase 1 Part 3 ongoing (MetaVia/Dong-A ST)
FDA status
DA-1726 is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Part 3 began in April 2026; dose-titration completion was announced in July. Sixteen-week results are expected in Q4 2026.
WADA status
Prohibited at all times under WADA's 2026 S0 rule for unapproved pharmacological substances. DA-1726 is investigational and need not be named individually for this rule to apply.
Prescribability
No — Investigational (Phase 1)
Availability
DA-1726 remains investigational and unavailable as an approved prescription medicine. Phase 1 Part 3 began in April 2026; 16-week results are expected in Q4 2026. Later-stage trials and regulatory review would be needed before approval.

International status

  • US

    Investigational — Phase 1 Part 3 ongoing (MetaVia/Dong-A ST)

  • Worldwide

    Investigational — early stage

Regulatory timeline(8)

  1. 2023
    DA-1726 IND submitted in December 2023; first human dosing followed in April 2024.
  2. 2024
    Phase 1 MAD initiated; multiple dose cohorts (4 mg to 32 mg)
  3. 2025-11
    ObesityWeek 2025 — Phase 1 data presented (up to 32 mg), preclinical comparisons
  4. 2025-Q4
    Phase 1 extended to 48 mg cohort (8 weeks, non-titrated)
  5. 2026-01
    48 mg cohort results reported — 9.1% weight loss, liver stiffness reduction
  6. 2026-03
    IRB approval for Phase 1 Part 3 (dose titration to 48 mg and 64 mg over 16 weeks)
  7. 2026-04
    Phase 1 Part 3 dosing begins
  8. 2026-Q4 (expected)
    Phase 1 Part 3 data expected

Sources & FAQs

Research sources(3)

Frequently asked questions(3)

How is DA-1726 different from tirzepatide or semaglutide?

DA-1726 is a GLP-1/glucagon dual agonist (not GLP-1/GIP like tirzepatide). The glucagon component is believed to increase energy expenditure and directly target liver fat, potentially offering superior visceral fat loss and liver benefits. In preclinical studies, it showed comparable weight loss to tirzepatide while preserving more lean body mass.

What stage of development is DA-1726 in?

DA-1726 is in Phase 1 clinical trials as of April 2026. While early results are very promising (9.1% weight loss in 8 weeks), the drug has only been tested in small groups. Phase 2 and Phase 3 trials are needed before any regulatory submission could occur.

What makes DA-1726's early results notable?

The 9.1% weight loss at 8 weeks WITHOUT dose titration is remarkable for a Phase 1 study. Most GLP-1 drugs require weeks of slow dose escalation to manage GI side effects, but DA-1726 achieved this weight loss with no treatment discontinuations and only mild GI events.